Jade Biosciences (NASDAQ:JBIO) reported fourth-quarter and full-year 2025 financial results on Friday, highlighting a robust cash position and a clear clinical roadmap for its portfolio of monoclonal antibodies.
The San Francisco-based biotechnology firm ended the year with $336.2 million in cash, cash equivalents, and investments, a figure management expects will fund operations into the first half of 2028.
This liquidity surge follows the successful completion of private financings in 2025 that raised approximately $180 million.
The company's lead asset, JADE101, a potentially best-in-class anti-APRIL monoclonal antibody, remains on track for significant catalysts in 2026.
Jade expects to release interim Phase 1 data from healthy volunteers in the second quarter of 2026, which will inform dose selection for a Phase 2 trial in IgA nephropathy (IgAN) slated to begin mid-year.
Beyond its lead program, Jade is accelerating its broader pipeline, with first-in-human dosing for JADE201 (anti-BAFF-R) expected in Q2 2026 and the nomination of JADE301, which is scheduled for Phase 1 entry in the first half of 2027.